Punit Kumar Sarna, MD
Cardiovascular Disease (Cardiology) · Monroe
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 6 carriers
- Offices
- 2
Offices
2 locations · Carolinas Physicians Network Inc · 2,324 clinicians in this group
Looking this up.
Hospitals listed: Atrium Health Anson · Atrium Health Pineville · Atrium Health Union · Atrium Health University City · Carolinas Medical Center/Behav Health. That is not proof they admit you there this week.
Plans that list them
21 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sarna’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A98965 · Current
Licensed to practise in California · since 2007 · expires 2028-08-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Atrium Health AnsonWadesboro, NCAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPart of Advocate Health, which runs 58 hospitals in 6 states75% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Atrium Health PinevilleCharlotte, NCAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.301, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.366, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.29, Oct 2024 – Sep 2025
- Atrium Health UnionMonroe, NCAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.51 (0.79 to 2.24) · 4,367 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.273, Oct 2024 – Sep 2025
- Atrium Health University CityCharlotte, NCAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesPatients rate it 3 of 5 · 63% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.226, Oct 2024 – Sep 2025
- Carolinas Medical Center/Behav HealthCharlotte, NCAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Postoperative sepsis rate: 3.16 (1.09 to 5.23) · 3,662 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.339, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.326, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.324, Oct 2024 – Sep 2025
See every measure and the patient survey for Atrium Health Anson
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 38 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 174 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.45) · 255 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 246 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.59 (0 to 1.89) · 171 cases | No different | Jul 2022 – Jun 2024 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.5 · 43 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -10.6 · 32 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 59 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 37 cases | None | Jul 2023 – Jun 2025 |
| Room was "always" clean | 92% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 69% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 86% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 85% |
| Nurses "always" treated them with courtesy and respect | 92% |
| "Always" quiet at night | 70% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Atrium Health Pineville
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.301 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.366 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.29 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.04 to 1.88) · 1,762 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.77 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.76 (134.44 to 229.08) · 73 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 144 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.3 · 211 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 254 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 727 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.8 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 419 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 5,377 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0.02 to 0.38) · 9,921 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.05 to 0.42) · 10,190 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.39 (1.5 to 5.28) · 2,165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.39 (0 to 2.77) · 879 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.88 (0.51 to 3.26) · 2,044 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.19 (4.82 to 15.56) · 846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.31 (0.94 to 7.68) · 823 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.52 (0.1 to 2.95) · 511 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.37 to 1.52) · 8,605 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 218 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.418 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.493 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.6 · 1,046 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.7 · 288 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 30 · 835 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.6 · 1,093 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.3 · 164 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.1 · 347 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.8 to 16.7) · 982 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 731 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,299 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 59% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Atrium Health Union
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.51 (0.79 to 2.24) · 4,367 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.273 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 658 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.18 (0.81 to 1.55) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 172.19 (111.77 to 232.6) · 32 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 433 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 590 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 418 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,280 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 5,373 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.14 to 0.54) · 5,285 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.51 (1.19 to 5.83) · 569 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.53 (0 to 3.19) · 118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.12 (0.47 to 3.78) · 533 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.94 (0 to 15.7) · 127 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.83 (0.66 to 9) · 115 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.17) · 159 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 68 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.736 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.949 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 118 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 817 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 30.2 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 3.1 · 605 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 949 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 311 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (9.6 to 16.8) · 492 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 382 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,026 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 62% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Atrium Health University City
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.226 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 396 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.01 (0.57 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 151 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 163 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 1,357 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,993 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.59 (1.09 to 6.09) · 228 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.21 (0.52 to 3.9) · 208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.91 (0 to 18.84) · 47 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.17 (0.86 to 9.49) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.07 (0.55 to 3.58) · 77 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.74 (0 to 1.73) · 1,771 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 30 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.435 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.988 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.432 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.222 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 364 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 25.1 · 178 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1 · 176 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 327 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 30 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 123 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (9.9 to 18.3) · 89 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 146 cases | No different | Jan 2024 – Dec 2024 |
What patients said (954 patients answered, 12% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 60% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
See every measure and the patient survey for Carolinas Medical Center/Behav Health
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 3.16 (1.09 to 5.23) · 3,662 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.339 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.326 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.324 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.1 (0.38 to 1.82) · 3,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.7 to 1.06) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 180.59 (151.25 to 209.92) · 340 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 99 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.7 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 385 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 529 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.2 · 698 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 7,580 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0.03 to 0.36) · 14,609 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.09 to 0.42) · 15,273 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.07 (1.8 to 4.34) · 6,259 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.16 (0.1 to 2.22) · 3,788 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.89 (1.93 to 3.85) · 5,917 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.61 (4.58 to 10.64) · 3,685 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.49 (0.21 to 2.78) · 1,563 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.37 to 1.16) · 12,904 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 304 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.01 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.797 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.039 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 374 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 909 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 7.7 · 223 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 16.5 · 452 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.7 · 538 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 929 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (4.4 to 6.1) · 1,952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.6 (9.5 to 12) · 1,952 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 284 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.8 · 369 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (10.8 to 17.9) · 1,280 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.9 to 1.2) · 1,810 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,371 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$126,739
Medicare paid this office $126,739 for 1,253 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 330 | $26,960 | $81 |
| New patient visit (60+ min) | 111 | $18,205 | $164 |
| Long return visit (40+ min) | 108 | $13,908 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 254 | $13,268 | $51 |
| Return visit (30+ min) | 88 | $10,961 | $91 |
See all 27 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 330 | $26,960 | $81 |
| New patient visit (60+ min) | 111 | $18,205 | $164 |
| Long return visit (40+ min) | 108 | $13,908 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 254 | $13,268 | $51 |
| Return visit (30+ min) | 88 | $10,961 | $91 |
| Critical care, first 30-74 minutes | 23 | $9,713 | $159 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $6,759 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $3,735 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $3,578 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $2,547 | $91 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 118 | $2,282 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 201 | $2,116 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 347 | $2,087 | $5 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $2,084 | $58 |
| External shock to heart to regulate heart beat | 16 | $1,088 | $64 |
| Injection, perflutren lipid microspheres, per ml | 22 | $899 | $33 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $883 | $80 |
| Ultrasound of heart, follow-up | 11 | $570 | $52 |
| Heart muscle strain imaging | 17 | $471 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 40 | $409 | $10 |
| Ultrasound of heart, follow-up | 17 | $322 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $158 | $14 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $149 | $14 |
| Heart muscle strain imaging | 18 | $149 | $8 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 11 | $97 | $9 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 17 | $92 | $5 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 28 | $66 | $2 |
Who their Medicare patients are
1,253 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 18% · Women 53% · Also on Medicaid 11% · Health risk score 1.76. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 50% · Atrial fibrillation 40% · Heart failure 38% · Chronic kidney disease 37% · Diabetes 35% · Depression 26% · COPD 24% · Cancer 18% · Stroke 16% · Dementia 12%.
The office billed $636,983, Medicare allowed $168,925 and paid $126,739; for 2,404 services of 47 kinds; $899 of it was for drugs given in the office and $125,840 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,253 | 2,404 | 77 | 1.76 | $636,983 | $126,739 |
| 2023 | 1,319 | 4,408 | 79 | 1.48 | $1,709,295 | $397,945 |
| 2022 | 1,219 | 4,491 | 79 | 1.37 | $1,671,023 | $402,905 |
| 2021 | 1,690 | 6,083 | 79 | 1.52 | $2,031,197 | $479,278 |
| 2020 | 1,043 | 4,988 | 79 | 1.43 | $2,115,819 | $467,185 |
| 2019 | 1,401 | 6,900 | 79 | 1.45 | $3,053,269 | $664,331 |
| 2018 | 998 | 3,456 | 77 | 1.99 | $1,641,920 | $291,813 |
| 2017 | 1,115 | 3,383 | 74 | 2.49 | $1,700,944 | $263,694 |
| 2016 | 951 | 2,356 | 74 | 2.00 | $1,043,570 | $178,281 |
| 2015 | 796 | 2,361 | 74 | 1.49 | $627,639 | $176,875 |
| 2014 | 34 | 71 | 74 | 1.05 | $11,747 | $5,434 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 26 services
| Return visit (30+ min) | 419 | $104,634 | $109 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 101 | $47,869 | $474 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 225 | $44,021 | $190 |
| Ultrasound of both sides of head and neck blood flow | 129 | $25,307 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $24,077 | $107 |
| Long return visit (40+ min) | 103 | $21,084 | $169 |
| Critical care, first 30-74 minutes | 32 | $15,451 | $186 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 106 | $15,289 | $73 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $12,247 | $141 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 33 | $10,259 | $285 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 161 | $9,607 | $58 |
| New patient visit (60+ min) | 45 | $8,554 | $190 |
| Injection, regadenoson, 0.1 mg | 48 | $8,454 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 114 | $7,970 | $70 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 291 | $7,474 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 353 | $5,809 | $13 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 14 | $4,247 | $303 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 371 | $3,466 | $7 |
| Telephone medical discussion with physician, 21-30 minutes | 32 | $3,169 | $81 |
| Ultrasound of heart with probe in esophagus, with report | 25 | $2,583 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,568 | $71 |
| External shock to heart to regulate heart beat | 14 | $1,498 | $94 |
| Programming of dual lead pacemaker system | 19 | $944 | $31 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 41 | $849 | $20 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 40 | $503 | $12 |
| Blood test, clotting time | 23 | $231 | $4 |
2022: 27 services
| Return visit (30+ min) | 411 | $112,086 | $111 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 132 | $62,653 | $475 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 221 | $45,022 | $200 |
| Ultrasound of both sides of head and neck blood flow | 166 | $31,974 | $193 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 137 | $23,729 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $18,250 | $94 |
| Injection, regadenoson, 0.1 mg | 75 | $14,425 | None |
| Critical care, first 30-74 minutes | 20 | $10,356 | $192 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 144 | $10,267 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,644 | $173 |
| New patient visit (60+ min) | 45 | $8,487 | $189 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 294 | $8,047 | $21 |
| Long return visit (40+ min) | 41 | $6,694 | $163 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 87 | $5,690 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 319 | $5,412 | $13 |
| Telephone medical discussion with physician, 21-30 minutes | 39 | $4,641 | $99 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 296 | $2,865 | $7 |
| External shock to heart to regulate heart beat | 20 | $2,347 | $98 |
| Programming of dual lead pacemaker system | 25 | $1,584 | $34 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,550 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,502 | $65 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 12 | $1,277 | $71 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 56 | $1,268 | $22 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 56 | $866 | $15 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $550 | $25 |
| Blood test, clotting time | 43 | $501 | $4 |
| Heart rhythm recording of continous external ekg over 8-15 days | 21 | $341 | $15 |
2021: 31 services
| Return visit (30+ min) | 379 | $135,505 | $118 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 397 | $80,490 | $193 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 115 | $60,462 | $455 |
| Ultrasound of both sides of head and neck blood flow | 166 | $35,411 | $198 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 117 | $20,366 | $87 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 458 | $16,633 | $21 |
| Injection, regadenoson, 0.1 mg | 85 | $15,784 | None |
| Long return visit (40+ min) | 78 | $14,295 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $13,068 | $95 |
| New patient visit (60+ min) | 60 | $10,813 | $180 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,996 | $176 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 120 | $8,696 | $72 |
| Critical care, first 30-74 minutes | 24 | $8,508 | $198 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 733 | $7,209 | $8 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 315 | $5,666 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 75 | $4,832 | $62 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $3,477 | $248 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 17 | $2,180 | $81 |
| Programming of dual lead pacemaker system | 32 | $1,919 | $35 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,915 | $66 |
| Blood test, clotting time | 74 | $1,703 | $4 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 57 | $1,449 | $23 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,407 | $94 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 57 | $1,060 | $16 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $690 | $49 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $481 | $24 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $417 | $26 |
| Heart rhythm recording of continous external ekg over 8-15 days | 18 | $286 | $16 |
| Ultrasound of heart blood flow, valves and chambers | 15 | $236 | $16 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $114 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | $41 | $3 |
2020: 26 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 193 | $99,462 | $507 |
| Return visit (30+ min) | 321 | $94,802 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 368 | $78,670 | $204 |
| Ultrasound of both sides of head and neck blood flow | 166 | $33,234 | $197 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 177 | $29,891 | $83 |
| Injection, regadenoson, 0.1 mg | 105 | $19,911 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 470 | $16,451 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 81 | $16,216 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 175 | $12,682 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $11,022 | $184 |
| Critical care, first 30-74 minutes | 17 | $7,340 | $198 |
| New patient visit (60+ min) | 30 | $5,413 | $180 |
| Long return visit (40+ min) | 36 | $4,920 | $129 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 19 | $4,643 | $244 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 205 | $3,848 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 49 | $3,407 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $3,213 | $107 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 20 | $2,254 | $73 |
| Blood test, clotting time | 100 | $1,893 | $4 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $1,728 | $66 |
| Programming of dual lead pacemaker system | 25 | $1,563 | $38 |
| External ekg recording for more than 48 hours up to 21 days | 33 | $1,097 | $28 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,082 | $98 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 33 | $959 | $25 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $892 | $56 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $486 | $27 |
2019: 34 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 326 | $166,292 | $507 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 450 | $94,637 | $202 |
| Return visit (30+ min) | 308 | $61,942 | $101 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 296 | $50,619 | $85 |
| Ultrasound of both sides of head and neck blood flow | 221 | $45,275 | $203 |
| Injection, regadenoson, 0.1 mg | 192 | $34,900 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 126 | $31,911 | $94 |
| Long return visit (40+ min) | 254 | $29,078 | $112 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 584 | $23,348 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 303 | $21,577 | $71 |
| Critical care, first 30-74 minutes | 32 | $19,622 | $198 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $17,317 | $179 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 37 | $8,627 | $227 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 115 | $7,744 | $63 |
| Nuclear medicine study of heart muscle at rest and with stress and spect | 11 | $7,688 | $366 |
| New patient visit (60+ min) | 27 | $4,796 | $178 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 210 | $4,312 | $16 |
| Blood test, clotting time | 130 | $2,966 | $4 |
| Ultrasound of heart with probe in esophagus, with report | 28 | $2,913 | $100 |
| Programming of dual lead pacemaker system | 30 | $2,828 | $61 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 15 | $2,229 | $97 |
| External shock to heart to regulate heart beat | 20 | $2,146 | $102 |
| Ultrasound of heart blood flow, valves and chambers | 36 | $1,700 | $46 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 16 | $1,666 | $83 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,588 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 39 | $946 | $24 |
| Short return visit (20+ min) | 13 | $861 | $66 |
| External ekg recording for more than 48 hours up to 21 days | 24 | $680 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 24 | $638 | $25 |
| Ultrasound of heart blood flow, valves and chambers | 25 | $441 | $17 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 15 | $401 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 13 | $364 | $28 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 19 | $222 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 24 | $74 | $3 |
2018: 28 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 124 | $54,477 | $439 |
| Return visit (30+ min) | 327 | $47,723 | $81 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 241 | $44,377 | $182 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 96 | $18,324 | $95 |
| Injection, regadenoson, 0.1 mg | 93 | $16,348 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 237 | $14,629 | $59 |
| Long return visit (40+ min) | 113 | $14,267 | $123 |
| Ultrasound of both sides of head and neck blood flow | 69 | $12,847 | $186 |
| New patient visit (60+ min) | 62 | $9,944 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $7,677 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $5,881 | $111 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 95 | $5,479 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 292 | $5,429 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 172 | $4,958 | $21 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 28 | $4,878 | $87 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $4,143 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,342 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,547 | $182 |
| Ultrasound of heart with probe in esophagus, with report | 22 | $2,115 | $92 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 25 | $1,476 | $59 |
| Programming of multiple lead implantable defibrillator system | 14 | $1,105 | $69 |
| Blood test, clotting time | 99 | $770 | $5 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $574 | $41 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 28 | $342 | $12 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 15 | $282 | $15 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $183 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $76 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 13 | $34 | $3 |
2017: 27 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 237 | $44,165 | $181 |
| Return visit (30+ min) | 266 | $38,611 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 612 | $32,293 | $49 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 75 | $30,338 | $405 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 171 | $19,245 | $106 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 76 | $14,236 | $94 |
| Long return visit (40+ min) | 112 | $13,641 | $115 |
| Injection, regadenoson, 0.1 mg | 61 | $10,587 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 110 | $10,192 | $57 |
| New patient visit (60+ min) | 58 | $9,143 | $158 |
| New patient visit (45+ min) | 60 | $7,197 | $120 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 315 | $5,847 | $13 |
| Ultrasound of heart with probe in esophagus, with report | 44 | $3,868 | $88 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 61 | $3,320 | $54 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $3,126 | $223 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 43 | $3,045 | $66 |
| External shock to heart to regulate heart beat | 28 | $2,569 | $89 |
| Ultrasound of both sides of head and neck blood flow | 17 | $2,283 | $134 |
| Programming of multiple lead implantable defibrillator system | 23 | $1,653 | $61 |
| Short return visit (20+ min) | 20 | $1,061 | $53 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $880 | $80 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 44 | $499 | $10 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 13 | $289 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $249 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $167 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 39 | $101 | $3 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 13 | $88 | $7 |
2016: 24 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 131 | $25,074 | $189 |
| Return visit (30+ min) | 235 | $24,228 | $78 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 411 | $22,692 | $51 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 70 | $20,718 | $296 |
| New patient visit (45+ min) | 106 | $13,401 | $126 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 52 | $9,824 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $6,845 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 53 | $6,454 | $58 |
| Injection, regadenoson, 0.1 mg | 38 | $6,296 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $6,086 | $111 |
| Long return visit (40+ min) | 48 | $5,801 | $118 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 267 | $3,876 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,761 | $84 |
| Short return visit (20+ min) | 81 | $3,506 | $40 |
| Ultrasound of heart with probe in esophagus, with report | 24 | $2,479 | $99 |
| New patient visit (60+ min) | 14 | $2,355 | $168 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 38 | $2,078 | $55 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 30 | $1,689 | $56 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,320 | $66 |
| New patient visit (30+ min) | 15 | $1,137 | $76 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $900 | $75 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 24 | $411 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 24 | $267 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $45 | $3 |
2015: 21 services
| Return visit (30+ min) | 198 | $29,198 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $24,478 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 137 | $23,371 | $162 |
| New patient visit (45+ min) | 156 | $18,970 | $122 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 83 | $16,201 | $188 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 255 | $12,966 | $50 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 135 | $8,765 | $65 |
| Short return visit (20+ min) | 110 | $7,234 | $58 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 34 | $7,145 | $204 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 16 | $4,236 | $132 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 231 | $3,715 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $2,586 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,492 | $108 |
| Ultrasound of heart with probe in esophagus, with report | 25 | $2,486 | $99 |
| Injection, regadenoson, 0.1 mg | 12 | $1,998 | None |
| External shock to heart to regulate heart beat | 17 | $1,830 | $96 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 86 | $1,548 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 86 | $1,010 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 15 | $832 | $55 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 24 | $524 | $22 |
| External ekg recording for more than 48 hours up to 21 days | 25 | $484 | $19 |
2014: 2 services
| Return visit (30+ min) | 11 | $1,080 | $83 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 12 | $151 | $13 |
Medicaid work
$4,380 in 2024
Medicaid paid $4,380 for 255 billed services this clinician did in 2024, up to 112 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 90 | $3,610 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 153 | $735 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 12 | $35 |
| 2024 | 255 | 3 | 112 | $4,380 |
| 2023 | 353 | 3 | 95 | $2,270 |
| 2022 | 162 | 1 | 73 | $831 |
| 2021 | 458 | 1 | 87 | $1,765 |
| 2020 | 57 | 1 | 26 | $287 |
| 2019 | 69 | 1 | 36 | $426 |
| 2018 | 300 | 3 | 101 | $5,507 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 285 | $1,254 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 56 | $856 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $160 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 162 | $831 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 458 | $1,765 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 57 | $287 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 69 | $426 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 267 | $5,260 |
| Return visit (30+ min) | 20 | $244 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 13 | $4 |
Drugs they prescribed that Part D paid
$382,819
Pharmacies billed $382,819 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,273) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,962 generic and 311 brand-name prescriptions · $382,819 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 88 | $104,412 | $1,186 |
| Entresto | 43 | $65,724 | $1,528 |
| Jardiance | 57 | $62,593 | $1,098 |
| Xarelto | 26 | $39,102 | $1,504 |
| Repatha Sureclick | 18 | $14,713 | $817 |
See all 36 drugs
| Eliquis | 88 | $104,412 | $1,186 |
| Entresto | 43 | $65,724 | $1,528 |
| Jardiance | 57 | $62,593 | $1,098 |
| Xarelto | 26 | $39,102 | $1,504 |
| Repatha Sureclick | 18 | $14,713 | $817 |
| Repatha | 12 | $10,026 | $835 |
| Rosuvastatin | 251 | $3,885 | $15 |
| Metoprolol | 245 | $3,832 | $16 |
| Ezetimibe | 99 | $2,350 | $24 |
| Atorvastatin | 171 | $2,231 | $13 |
| Nebivolol | 31 | $1,742 | $56 |
| Losartan | 125 | $1,388 | $11 |
| Carvedilol | 104 | $916 | $9 |
| Flecainide Acetate | 29 | $859 | $30 |
| Amlodipine Besylate | 113 | $851 | $8 |
| Potassium Chloride | 20 | $830 | $42 |
| Lisinopril | 69 | $765 | $11 |
| Losartan-Hydrochlorothiazide | 45 | $699 | $16 |
| Valsartan | 35 | $643 | $18 |
| Diltiazem 24hr Er (Cd) | 22 | $586 | $27 |
| Amiodarone | 40 | $567 | $14 |
| Spironolactone | 72 | $485 | $7 |
| Isosorbide Mononitrate Er | 20 | $457 | $23 |
| Simvastatin | 25 | $366 | $15 |
| Torsemide | 15 | $340 | $23 |
| Benazepril | 29 | $328 | $11 |
| Clopidogrel | 27 | $277 | $10 |
| Furosemide | 46 | $260 | $6 |
| Warfarin | 18 | $243 | $14 |
| Nifedipine Er | 17 | $237 | $14 |
| Chlorthalidone | 16 | $233 | $15 |
| Triamterene-Hydrochlorothiazid | 13 | $164 | $13 |
| Pravastatin | 12 | $154 | $13 |
| Metoprolol | 33 | $128 | $4 |
| Atenolol | 14 | $95 | $7 |
| Hydrochlorothiazide | 24 | $82 | $3 |
Year by year
| 2024 | 2,273 | 564 | 0% (0) | 14% | $382,819 |
| 2023 | 3,678 | 462 | None | 13% | $629,634 |
| 2022 | 3,409 | 420 | 0% (0) | None | $452,858 |
| 2021 | 3,329 | 418 | 0% (0) | 10% | $355,025 |
| 2020 | 2,987 | 380 | None | 11% | $290,547 |
| 2019 | 2,589 | 488 | 0% (0) | 15% | $252,541 |
| 2018 | 2,814 | 404 | 0% (0) | 15% | $229,742 |
| 2017 | 2,492 | 385 | 0% (0) | 17% | $162,427 |
| 2016 | 1,571 | 301 | 0% (0) | 13% | $73,137 |
| 2015 | 1,225 | 181 | None | 17% | $49,166 |
| 2014 | 557 | 50 | 0% (0) | 18% | $19,957 |
| 2013 | 480 | 44 | 0% (0) | 21% | $21,229 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 46 drugs
| Eliquis | 125 | $164,289 | $1,314 |
| Xarelto | 64 | $91,223 | $1,425 |
| Jardiance | 56 | $81,934 | $1,463 |
| Entresto | 68 | $81,287 | $1,195 |
| Praluent | 20 | $23,824 | $1,191 |
| Farxiga | 18 | $15,503 | $861 |
| Metoprolol | 392 | $9,131 | $23 |
| Rosuvastatin | 289 | $7,487 | $26 |
| Ezetimibe | 104 | $5,613 | $54 |
| Atorvastatin | 381 | $5,373 | $14 |
| Amiodarone | 53 | $4,952 | $93 |
| Flecainide Acetate | 83 | $4,142 | $50 |
| Nebivolol | 46 | $3,137 | $68 |
| Ranolazine Er | 17 | $2,853 | $168 |
| Losartan | 204 | $2,693 | $13 |
| Potassium Chloride | 49 | $2,527 | $52 |
| Diltiazem 24hr Er (Cd) | 50 | $2,173 | $43 |
| Carvedilol | 137 | $2,004 | $15 |
| Valsartan | 46 | $1,918 | $42 |
| Amlodipine Besylate | 192 | $1,750 | $9 |
| Lisinopril | 121 | $1,336 | $11 |
| Simvastatin | 87 | $1,230 | $14 |
| Losartan-Hydrochlorothiazide | 54 | $1,207 | $22 |
| Diltiazem 24hr Er (Xr) | 26 | $1,194 | $46 |
| Clopidogrel | 62 | $1,115 | $18 |
| Isosorbide Mononitrate Er | 26 | $1,114 | $43 |
| Torsemide | 39 | $1,083 | $28 |
| Nifedipine Er | 13 | $879 | $68 |
| Chlorthalidone | 28 | $799 | $29 |
| Spironolactone | 69 | $798 | $12 |
| Telmisartan | 17 | $798 | $47 |
| Fenofibrate | 15 | $751 | $50 |
| Benazepril | 42 | $682 | $16 |
| Pravastatin | 35 | $629 | $18 |
| Hydralazine | 14 | $558 | $40 |
| Verapamil Er | 11 | $505 | $46 |
| Amlodipine Besylate-Benazepril | 16 | $487 | $30 |
| Hydrochlorothiazide | 69 | $482 | $7 |
| Triamterene-Hydrochlorothiazid | 25 | $414 | $17 |
| Furosemide | 73 | $405 | $6 |
| Pantoprazole | 17 | $373 | $22 |
| Warfarin | 20 | $265 | $13 |
| Metoprolol | 27 | $225 | $8 |
| Atenolol | 22 | $218 | $10 |
| Propranolol | 11 | $71 | $6 |
| Amoxicillin | 19 | $27 | $1 |
2022: 50 drugs
| Eliquis | 137 | $169,197 | $1,235 |
| Xarelto | 76 | $75,607 | $995 |
| Entresto | 32 | $48,616 | $1,519 |
| Farxiga | 14 | $13,767 | $983 |
| Metoprolol | 373 | $7,902 | $21 |
| Rosuvastatin | 216 | $6,054 | $28 |
| Atorvastatin | 368 | $5,904 | $16 |
| Flecainide Acetate | 75 | $5,174 | $69 |
| Nebivolol | 36 | $3,812 | $106 |
| Ezetimibe | 40 | $3,282 | $82 |
| Losartan | 224 | $2,759 | $12 |
| Ranolazine Er | 16 | $2,726 | $170 |
| Diltiazem 24hr Er (Cd) | 65 | $2,377 | $37 |
| Potassium Chloride | 50 | $2,176 | $44 |
| Telmisartan | 21 | $1,969 | $94 |
| Carvedilol | 136 | $1,959 | $14 |
| Amiodarone | 47 | $1,853 | $39 |
| Niacin Er | 13 | $1,793 | $138 |
| Losartan-Hydrochlorothiazide | 53 | $1,774 | $33 |
| Chlorthalidone | 38 | $1,394 | $37 |
| Valsartan | 35 | $1,388 | $40 |
| Fenofibrate | 19 | $1,184 | $62 |
| Lisinopril | 127 | $1,183 | $9 |
| Amlodipine Besylate | 156 | $1,129 | $7 |
| Simvastatin | 88 | $974 | $11 |
| Spironolactone | 84 | $968 | $12 |
| Bumetanide | 11 | $908 | $83 |
| Clopidogrel | 57 | $883 | $15 |
| Isosorbide Mononitrate Er | 33 | $755 | $23 |
| Nifedipine Er | 11 | $624 | $57 |
| Hydralazine | 19 | $598 | $31 |
| Warfarin | 22 | $566 | $26 |
| Nitroglycerin | 24 | $506 | $21 |
| Valsartan-Hydrochlorothiazide | 13 | $502 | $39 |
| Benazepril | 37 | $487 | $13 |
| Olmesartan Medoxomil | 11 | $419 | $38 |
| Metoprolol | 47 | $419 | $9 |
| Diltiazem 24hr Er (Xr) | 14 | $416 | $30 |
| Hydrochlorothiazide | 79 | $385 | $5 |
| Furosemide | 53 | $343 | $6 |
| Pantoprazole | 14 | $329 | $23 |
| Amlodipine Besylate-Benazepril | 14 | $321 | $23 |
| Pravastatin | 28 | $321 | $11 |
| Doxazosin Mesylate | 16 | $278 | $17 |
| Atenolol | 16 | $276 | $17 |
| Triamterene-Hydrochlorothiazid | 20 | $245 | $12 |
| Gabapentin | 11 | $184 | $17 |
| Ramipril | 12 | $142 | $12 |
| Lisinopril-Hydrochlorothiazide | 13 | $88 | $7 |
| Amoxicillin | 24 | $35 | $1 |
2021: 47 drugs
| Eliquis | 115 | $134,161 | $1,167 |
| Xarelto | 79 | $69,935 | $885 |
| Entresto | 11 | $19,206 | $1,746 |
| Rosuvastatin | 196 | $9,792 | $50 |
| Bystolic | 21 | $7,921 | $377 |
| Metoprolol | 327 | $6,865 | $21 |
| Atorvastatin | 344 | $6,503 | $19 |
| Flecainide Acetate | 51 | $4,003 | $78 |
| Amiodarone | 57 | $3,478 | $61 |
| Losartan | 230 | $3,263 | $14 |
| Telmisartan | 27 | $2,753 | $102 |
| Diltiazem 24hr Er (Cd) | 67 | $2,305 | $34 |
| Ezetimibe | 22 | $2,103 | $96 |
| Potassium Chloride | 32 | $1,898 | $59 |
| Carvedilol | 154 | $1,878 | $12 |
| Dilt-Xr | 34 | $1,835 | $54 |
| Chlorthalidone | 38 | $1,334 | $35 |
| Valsartan | 15 | $1,216 | $81 |
| Losartan-Hydrochlorothiazide | 38 | $1,198 | $32 |
| Lisinopril | 143 | $1,189 | $8 |
| Isosorbide Mononitrate Er | 52 | $1,114 | $21 |
| Simvastatin | 106 | $1,096 | $10 |
| Nitroglycerin | 31 | $1,040 | $34 |
| Amlodipine Besylate | 166 | $1,028 | $6 |
| Warfarin | 44 | $961 | $22 |
| Digoxin | 23 | $917 | $40 |
| Torsemide | 13 | $907 | $70 |
| Spironolactone | 59 | $857 | $15 |
| Amlodipine-Atorvastatin | 12 | $819 | $68 |
| Pravastatin | 31 | $771 | $25 |
| Metoprolol | 60 | $701 | $12 |
| Clopidogrel | 63 | $697 | $11 |
| Ramipril | 24 | $623 | $26 |
| Fenofibrate | 12 | $614 | $51 |
| Hydrochlorothiazide | 83 | $535 | $6 |
| Benazepril | 34 | $511 | $15 |
| Atenolol | 40 | $456 | $11 |
| Furosemide | 59 | $439 | $7 |
| Triamterene-Hydrochlorothiazid | 26 | $431 | $17 |
| Cartia Xt | 11 | $422 | $38 |
| Olmesartan Medoxomil | 11 | $421 | $38 |
| Valsartan-Hydrochlorothiazide | 11 | $406 | $37 |
| Hydralazine | 31 | $399 | $13 |
| Pantoprazole | 13 | $268 | $21 |
| Sotalol | 17 | $227 | $13 |
| Lisinopril-Hydrochlorothiazide | 12 | $160 | $13 |
| Metformin | 11 | $92 | $8 |
2020: 42 drugs
| Eliquis | 86 | $86,087 | $1,001 |
| Xarelto | 77 | $69,262 | $900 |
| Entresto | 16 | $15,140 | $946 |
| Bystolic | 21 | $7,574 | $361 |
| Rosuvastatin | 123 | $7,413 | $60 |
| Atorvastatin | 286 | $6,331 | $22 |
| Metoprolol | 266 | $5,637 | $21 |
| Amiodarone | 58 | $5,445 | $94 |
| Flecainide Acetate | 45 | $3,714 | $83 |
| Potassium Chloride | 40 | $3,190 | $80 |
| Losartan | 214 | $2,869 | $13 |
| Valsartan | 19 | $2,270 | $119 |
| Telmisartan | 15 | $1,997 | $133 |
| Carvedilol | 148 | $1,839 | $12 |
| Chlorthalidone | 51 | $1,680 | $33 |
| Amlodipine-Atorvastatin | 12 | $1,582 | $132 |
| Amlodipine Besylate | 182 | $1,428 | $8 |
| Digoxin | 27 | $1,326 | $49 |
| Simvastatin | 116 | $1,206 | $10 |
| Warfarin | 45 | $1,193 | $27 |
| Diltiazem 24hr Er (Cd) | 25 | $1,155 | $46 |
| Clopidogrel | 61 | $1,138 | $19 |
| Nitroglycerin | 28 | $1,125 | $40 |
| Losartan-Hydrochlorothiazide | 32 | $1,025 | $32 |
| Spironolactone | 71 | $994 | $14 |
| Dilt-Xr | 15 | $919 | $61 |
| Ezetimibe | 15 | $910 | $61 |
| Hydrochlorothiazide | 92 | $879 | $10 |
| Benazepril-Hydrochlorothiazide | 12 | $876 | $73 |
| Pravastatin | 30 | $812 | $27 |
| Lisinopril | 104 | $778 | $7 |
| Isosorbide Mononitrate Er | 31 | $759 | $24 |
| Furosemide | 97 | $730 | $8 |
| Benazepril | 45 | $669 | $15 |
| Ramipril | 26 | $660 | $25 |
| Metoprolol | 64 | $613 | $10 |
| Olmesartan Medoxomil | 12 | $584 | $49 |
| Torsemide | 24 | $500 | $21 |
| Hydralazine | 23 | $467 | $20 |
| Cartia Xt | 13 | $431 | $33 |
| Atenolol | 34 | $401 | $12 |
| Triamterene-Hydrochlorothiazid | 20 | $299 | $15 |
2019: 38 drugs
| Eliquis | 97 | $75,210 | $775 |
| Xarelto | 83 | $65,313 | $787 |
| Entresto | 20 | $13,806 | $690 |
| Metoprolol | 206 | $6,163 | $30 |
| Rosuvastatin | 92 | $6,133 | $67 |
| Atorvastatin | 203 | $5,009 | $25 |
| Bystolic | 16 | $4,646 | $290 |
| Amiodarone | 54 | $3,336 | $62 |
| Flecainide Acetate | 56 | $3,277 | $59 |
| Potassium Chloride | 42 | $3,237 | $77 |
| Amlodipine Besylate | 192 | $2,297 | $12 |
| Chlorthalidone | 59 | $1,793 | $30 |
| Carvedilol | 147 | $1,781 | $12 |
| Losartan | 154 | $1,658 | $11 |
| Digoxin | 27 | $1,650 | $61 |
| Warfarin | 66 | $1,561 | $24 |
| Toprol Xl | 15 | $1,452 | $97 |
| Bumetanide | 14 | $1,303 | $93 |
| Simvastatin | 96 | $1,153 | $12 |
| Ramipril | 26 | $900 | $35 |
| Furosemide | 110 | $861 | $8 |
| Isosorbide Mononitrate Er | 30 | $848 | $28 |
| Diltiazem 24hr Er (Cd) | 13 | $800 | $62 |
| Dilt-Xr | 13 | $784 | $60 |
| Spironolactone | 64 | $764 | $12 |
| Valsartan-Hydrochlorothiazide | 15 | $753 | $50 |
| Clopidogrel | 40 | $696 | $17 |
| Lisinopril | 79 | $685 | $9 |
| Pravastatin | 21 | $681 | $32 |
| Benazepril | 55 | $664 | $12 |
| Metoprolol | 71 | $586 | $8 |
| Losartan-Hydrochlorothiazide | 37 | $559 | $15 |
| Ezetimibe | 11 | $425 | $39 |
| Hydralazine | 14 | $363 | $26 |
| Hydrochlorothiazide | 43 | $358 | $8 |
| Atenolol | 23 | $261 | $11 |
| Nitroglycerin | 14 | $251 | $18 |
| Ondansetron | 12 | $156 | $13 |
2018: 36 drugs
| Eliquis | 123 | $70,286 | $571 |
| Xarelto | 114 | $65,869 | $578 |
| Entresto | 19 | $12,617 | $664 |
| Metoprolol | 257 | $7,883 | $31 |
| Pradaxa | 19 | $7,603 | $400 |
| Ranexa | 15 | $6,975 | $465 |
| Amiodarone | 76 | $5,599 | $74 |
| Chlorthalidone | 83 | $3,589 | $43 |
| Pacerone | 16 | $2,812 | $176 |
| Amlodipine Besylate | 253 | $2,451 | $10 |
| Atorvastatin | 103 | $2,220 | $22 |
| Carvedilol | 301 | $1,912 | $6 |
| Flecainide Acetate | 59 | $1,875 | $32 |
| Bumetanide | 26 | $1,853 | $71 |
| Nifedipine Er | 19 | $1,549 | $82 |
| Losartan | 217 | $1,544 | $7 |
| Lisinopril | 184 | $1,375 | $7 |
| Eplerenone | 18 | $1,218 | $68 |
| Isosorbide Mononitrate Er | 46 | $1,152 | $25 |
| Rosuvastatin | 21 | $1,083 | $52 |
| Spironolactone | 101 | $892 | $9 |
| Clopidogrel | 88 | $870 | $10 |
| Valsartan | 15 | $702 | $47 |
| Metoprolol | 107 | $608 | $6 |
| Dilt-Xr | 14 | $433 | $31 |
| Pantoprazole | 27 | $399 | $15 |
| Benazepril | 41 | $378 | $9 |
| Furosemide | 106 | $372 | $4 |
| Sotalol | 18 | $340 | $19 |
| Hydralazine | 29 | $326 | $11 |
| Warfarin | 15 | $313 | $21 |
| Atenolol | 28 | $256 | $9 |
| Simvastatin | 18 | $224 | $12 |
| Digoxin | 11 | $222 | $20 |
| Hydrochlorothiazide | 32 | $164 | $5 |
| Cilostazol | 14 | $118 | $8 |
2017: 30 drugs
| Xarelto | 125 | $54,724 | $438 |
| Eliquis | 91 | $43,731 | $481 |
| Pradaxa | 22 | $9,619 | $437 |
| Metoprolol | 229 | $6,308 | $28 |
| Brilinta | 12 | $5,370 | $447 |
| Bystolic | 32 | $3,897 | $122 |
| Amiodarone | 33 | $2,940 | $89 |
| Chlorthalidone | 54 | $2,108 | $39 |
| Flecainide Acetate | 65 | $1,859 | $29 |
| Carvedilol | 285 | $1,769 | $6 |
| Atorvastatin | 115 | $1,699 | $15 |
| Valsartan | 30 | $1,475 | $49 |
| Nifedipine Er | 21 | $1,292 | $62 |
| Amlodipine Besylate | 227 | $1,200 | $5 |
| Lisinopril | 260 | $1,093 | $4 |
| Losartan | 152 | $1,071 | $7 |
| Rosuvastatin | 19 | $904 | $48 |
| Bumetanide | 16 | $721 | $45 |
| Clopidogrel | 58 | $664 | $11 |
| Spironolactone | 108 | $620 | $6 |
| Hydralazine | 39 | $588 | $15 |
| Metoprolol | 119 | $538 | $5 |
| Isosorbide Mononitrate Er | 36 | $455 | $13 |
| Sotalol | 18 | $280 | $16 |
| Furosemide | 68 | $211 | $3 |
| Benazepril | 23 | $205 | $9 |
| Atenolol | 35 | $175 | $5 |
| Simvastatin | 14 | $154 | $11 |
| Cilostazol | 12 | $102 | $8 |
| Hydrochlorothiazide | 14 | $59 | $4 |
2016: 24 drugs
| Eliquis | 45 | $22,383 | $497 |
| Xarelto | 34 | $14,919 | $439 |
| Pradaxa | 14 | $7,097 | $507 |
| Metoprolol | 144 | $4,085 | $28 |
| Valsartan | 17 | $2,649 | $156 |
| Atorvastatin | 67 | $1,645 | $25 |
| Lisinopril | 230 | $1,038 | $5 |
| Amiodarone | 14 | $893 | $64 |
| Amlodipine Besylate | 163 | $741 | $5 |
| Potassium Chloride | 19 | $686 | $36 |
| Losartan | 99 | $677 | $7 |
| Carvedilol | 116 | $642 | $6 |
| Isosorbide Mononitrate Er | 51 | $586 | $11 |
| Bumetanide | 12 | $556 | $46 |
| Spironolactone | 81 | $513 | $6 |
| Dilt-Xr | 19 | $506 | $27 |
| Metoprolol | 106 | $495 | $5 |
| Clopidogrel | 23 | $445 | $19 |
| Furosemide | 69 | $284 | $4 |
| Benazepril | 34 | $254 | $7 |
| Sotalol | 12 | $165 | $14 |
| Losartan-Hydrochlorothiazide | 17 | $84 | $5 |
| Hydrochlorothiazide | 14 | $66 | $5 |
| Atenolol | 12 | $44 | $4 |
2015: 22 drugs
| Xarelto | 37 | $15,880 | $429 |
| Eliquis | 23 | $11,154 | $485 |
| Metoprolol | 127 | $3,164 | $25 |
| Atorvastatin | 59 | $1,430 | $24 |
| Lisinopril | 197 | $710 | $4 |
| Bumetanide | 17 | $631 | $37 |
| Isosorbide Mononitrate Er | 58 | $539 | $9 |
| Metoprolol | 88 | $510 | $6 |
| Spironolactone | 100 | $483 | $5 |
| Amiodarone | 25 | $446 | $18 |
| Amlodipine Besylate | 91 | $377 | $4 |
| Clopidogrel | 22 | $307 | $14 |
| Losartan | 48 | $269 | $6 |
| Benazepril | 38 | $249 | $7 |
| Furosemide | 63 | $210 | $3 |
| Diltiazem 24hr Er | 16 | $206 | $13 |
| Carvedilol | 30 | $181 | $6 |
| Hydralazine | 11 | $166 | $15 |
| Nifedipine Er | 11 | $89 | $8 |
| Losartan-Hydrochlorothiazide | 15 | $85 | $6 |
| Hydrochlorothiazide | 14 | $63 | $5 |
| Atenolol | 11 | $32 | $3 |
2014: 15 drugs
| Fenofibrate | 14 | $1,782 | $127 |
| Atorvastatin | 76 | $1,294 | $17 |
| Metoprolol | 34 | $1,222 | $36 |
| Isosorbide Mononitrate Er | 60 | $927 | $15 |
| Carvedilol | 37 | $405 | $11 |
| Lisinopril | 50 | $388 | $8 |
| Torsemide | 14 | $307 | $22 |
| Hydralazine | 25 | $281 | $11 |
| Amlodipine Besylate | 29 | $262 | $9 |
| Pravastatin | 21 | $223 | $11 |
| Metoprolol | 45 | $202 | $4 |
| Potassium Chloride | 11 | $168 | $15 |
| Spironolactone | 20 | $121 | $6 |
| Clopidogrel | 12 | $75 | $6 |
| Furosemide | 11 | $46 | $4 |
2013: 16 drugs
| Effient | 13 | $3,694 | $284 |
| Fenofibrate | 22 | $2,635 | $120 |
| Zetia | 11 | $1,790 | $163 |
| Clopidogrel | 26 | $1,345 | $52 |
| Atorvastatin | 48 | $1,261 | $26 |
| Diovan | 11 | $1,093 | $99 |
| Eplerenone | 11 | $763 | $69 |
| Isosorbide Mononitrate Er | 46 | $741 | $16 |
| Carvedilol | 49 | $710 | $14 |
| Hydralazine | 19 | $577 | $30 |
| Metoprolol | 14 | $458 | $33 |
| Lisinopril | 45 | $263 | $6 |
| Amlodipine Besylate | 21 | $229 | $11 |
| Metoprolol | 31 | $229 | $7 |
| Pravastatin | 22 | $168 | $8 |
| Furosemide | 18 | $96 | $5 |
Money from drug and device companies
$296 in 2025
| 2025 | 2 | 3 | None | $296 |
| 2024 | 5 | 22 | None | $563 |
| 2023 | 14 | 37 | None | $1,021 |
| 2022 | 7 | 17 | None | $347 |
| 2021 | 14 | 67 | None | $1,402 |
| 2020 | 14 | 36 | None | $802 |
| 2019 | 9 | 29 | None | $728 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Heartflow | Ffrct | $272 | 2 payments
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $24 | 1 payment
|
See all 3 published payments
| Heartflow | Meals · 2025-08-26 | Ffrct | $119 |
| Heartflow | Meals · 2025-07-24 | Ffrct | $154 |
| Baxter Healthcare | Meals · 2025-06-06 | Hillrom - Carnation Ambulatory Monitor | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $563
| Philips North America | (5044) Mcot | $225 | 10 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $165 | 9 payments
|
| CVRx | Barostim Neo System | $130 | 1 payment
|
| Pfizer | Vyndaqel | $27 | 1 payment
|
| Lantheus Medical Imaging | Definity | $17 | 1 payment
|
2023: $1,021
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $210 | 6 payments
|
| Esperion Therapeutics | Nexletol | $147 | 7 payments
|
| Novo Nordisk | None | $122 | 1 payment
|
| Pfizer | Eliquis | $116 | 5 payments
|
| Alnylam Pharmaceuticals | Onpattro | $97 | 4 payments
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $57 | 2 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $49 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $49 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $42 | 2 payments
|
| Abbott Laboratories | Cardiomems | $32 | 2 payments
|
| Philips Electronics North America | (5044) Mcot | $30 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $27 | 1 payment
|
| Amgen | Repatha | $23 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $22 | 1 payment
|
2022: $347
| Esperion Therapeutics | Nexletol | $120 | 6 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $66 | 3 payments
|
| Pfizer | Eliquis | $66 | 3 payments
|
| Astellas Pharma US | Lexiscan | $42 | 2 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $19 | 1 payment
|
| Amgen | Repatha | $18 | 1 payment
|
| Novo Nordisk | Ozempic | $16 | 1 payment
|
2021: $1,402
| Esperion Therapeutics | Nexletol | $218 | 9 payments
|
| Janssen Pharmaceuticals | Xarelto | $184 | 11 payments
|
| Novo Nordisk | Ozempic | $178 | 6 payments
|
| Abbott Laboratories | Mitraclip System | $130 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $102 | 7 payments
|
| Astellas Pharma US | Lexiscan | $98 | 5 payments
|
| Novartis Pharmaceuticals | Entresto | $87 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $80 | 4 payments
|
| Amarin Pharma | Vascepa | $73 | 4 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $69 | 2 payments
|
| Kiniksa Pharmaceuticals | None | $51 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $50 | 3 payments
|
| Alnylam Pharmaceuticals | Onpattro | $44 | 2 payments
|
| Amgen | Repatha | $37 | 2 payments
|
2020: $802
| Abbott Laboratories | Quadra Assura Crt Defibrillator | $274 | 10 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $117 | 5 payments
|
| Astellas Pharma US | Lexiscan | $85 | 4 payments
|
| Esperion Therapeutics | Nexletol | $70 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $57 | 3 payments
|
| Amarin Pharma | Vascepa | $36 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $31 | 2 payments
|
| Pfizer | Eliquis | $25 | 1 payment
|
| Medtronic Vascular | Carelink | $22 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $21 | 1 payment
|
| Amgen | Corlanor | $20 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $19 | 1 payment
|
| Boston Scientific | Sq-Rx Pulse Generator | $12 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $11 | 1 payment
|
2019: $728
| Novartis Pharmaceuticals | Entresto | $280 | 9 payments
|
| Janssen Pharmaceuticals | Xarelto | $116 | 7 payments
|
| Abbott Laboratories | Cardiomems Hf System | $105 | 3 payments
|
| Amgen | Repatha | $83 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $78 | 1 payment
|
| Pfizer | Eliquis | $27 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $17 | 1 payment
|
| Medtronic Vascular | Reveal Linq | $13 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $9 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1659553923
- Licence
- CA A98965, NC 2014-01418California A98965: Current · expires 2028-08-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- NC 1659553923
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 2490 Hospital Dr, Ste 311, Mountain View, CA, 94040
- NPI first listed
- 2007-11-28
- NPI last updated
- 2023-12-08
- NPI record certified
- 2023-12-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 625 Lincoln Ave, San Jose, CA, 95126